Table 1 Clinical and genetic characteristics for all patients according to disease origin (de novo vs secondary or treatment related), n = 644.

From: ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation

 

All patients

De novo AML

Secondary or treatment-related AML

P

n = 644

n = 416

n = 228

Age at diagnosis, years

   

<0.001

   Median

59.0

56.0

62.1

 

   Range

14.3–76.5

14.3–76.5

27.1–74.7

 

Sex, n (%)

   

0.05

   Male

334

204 (49)

130 (57)

 

   Female

310

212 (51)

98 (43)

 

Hemoglobin, g/dL

   

0.69

   Median

8.9

9

8.9

 

   Range

3.2–15.7

3.2–15.7

5.4–15

 

Platelet count, ×109/L

   

0.25

   Median

63

65

59

 

   Range

1–950

2–950

1–547

 

WBC, ×109/L

   

0.01

   Median

6.5

8.6

5.3

 

   Range

0.1–432

0.5–385

0.1–432

 

Blood blasts, %

   

<0.001

   Median

 20

24

12

 

   Range

0–98

0–98

0–97

 

BM blasts, %

   

<0.001

   Median

 50

60

35

 

   Range

0–100

0–100

0–95

 

BM CD34+/CD38- burden, %

   

<0.001

   Median

0.7

0.5

1.1

 

   Range

0–89

0–75

0–89

 

Normal karyotype, n (%)

 

0.006

  

   Absent

329

192 (52)

137 (63)

 

   Present

259

180 (48)

79 (37)

 

ELN2017 genetic risk group, n (%)

   

<0.001

   Favorable

114

97 (33)

17 (12)

 

   Intermediate

129

84 (28)

45 (32)

 

   Adverse

195

115 (39)

80 (56)

 

NPM1, n (%)

   

<0.001

   Wild type

345

217 (71)

128 (86)

 

   Mutated

111

90 (29)

21 (14)

 

CEBPA, n (%)

  

0.73

 

   Wild type

326

232 (88)

94 (87)

 

   Mutated

45

31 (12)

14 (14)

 

FLT3-ITD, n (%)

   

<0.001

   Absent

358

224 (72)

134 (90)

 

   Present

103

88 (28)

15 (10)

 

FLT3-TKD, n (%)

   

0.003

   Wild type

379

248 (87)

131 (96)

 

   Mutated

42

37 (13)

5 (4)

 

RUNX1, n (%)

   

1

   Wild type

95

61 (85)

34 (85)

 

   Mutated

17

11 (15)

6 (15)

 

ASXL1, n (%)

   

0.41

   Wild type

95

63 (88)

32 (80)

 

   Mutated

17

9 (13)

8 (20)

 

TP53, n (%)

   

1

   Wild type

99

64 (89)

35 (88)

 

   Mutated

13

8 (11)

5 (13)

 
  1. ASXL1 additional sex combs-like 1 gene, BM bone marrow, BAALC brain and acute leukemia, cytogenetic gene, CEBPA CCAAT/enhancer-binding protein alpha gene, ELN European LeukemiaNet, FLT3-ITD internal tandem duplication of the FLT3 gene, Hb hemoglobin, MN1 meningioma 1 gene, NPM1 nucleophosmin 1 gene, PB peripheral blood, RUNX1 Runt-related transcription factor 1 gene, TP53 tumor protein 53 gene, WBC white blood count.
Back to article page